利奥西呱用于镰状细胞病合并高血压或蛋白尿患者(STERIO-SCD):一项随机、双盲、安慰剂对照的1-2期试验
这项1-2期随机双盲安慰剂对照试验纳入130例镰状细胞病合并1期高血压或蛋白尿的成人患者,按1:1随机分配接受利奥西呱(n=66)或安慰剂(n=64)治疗12周。利奥西呱组发生至少一次治疗出现严重不良事件的比例为22.7%,安慰剂组为31.3%,差异无统计学显著性;利奥西呱对全身血压有显著血流动力学效应。
要点
- 利奥西呱组治疗出现严重不良事件比例22.7% vs 安慰剂组31.3%,差异无统计学显著性
- 镰状细胞相关血管闭塞事件、疼痛严重程度及疼痛干扰两组相似
- 利奥西呱对全身血压有显著血流动力学效应,结果可为未来试验的效力计算提供参考
核心结论
- 利奥西呱安全,并对全身血压有显著的血流动力学效应。
- 研究结果提供了效应量和变异度的估计,将为未来试验的效力计算提供依据。
研究设计与样本
- 1-2期、随机、双盲、安慰剂对照试验。
- 纳入18岁及以上、经血红蛋白电泳或HPLC组分分析确诊镰状细胞病(血红蛋白SS、SC、Sβ-地中海贫血、SD或SO-Arab)且合并1期高血压或蛋白尿的患者。
- 2017年4月11日至2021年12月31日期间筛查165例,130例随机分配至利奥西呱组(n=66)或安慰剂组(n=64)。
- 两组均口服给药,起始1.0 mg每日三次,最高至2.5 mg每日三次(最高耐受剂量),疗程12周;若收缩压大于95 mm Hg且无低血压征象,每2周考虑增加0.5 mg,否则维持末次剂量。
- 主要结局为发生至少一次经判定的治疗出现严重不良事件的参与者比例,按意向性治疗分析。
主要发现
- 发生至少一次治疗出现严重不良事件的比例:利奥西呱组22.7%(n=15)vs 安慰剂组31.3%(n=20),差异-8.5%(90% CI -21.4 to 4.5;p=0.19)。
- 镰状细胞相关血管闭塞事件:利奥西呱组16.7%(n=11)vs 安慰剂组21.9%(n=14),差异-5.2%(-17.2 to 6.5;p=0.42)。
- 12周时平均疼痛严重程度:利奥西呱组3.18 vs 安慰剂组3.32,校正平均差异-0.14(-0.70 to 0.42;p=0.69)。
- 12周时疼痛干扰:利奥西呱组3.15 vs 安慰剂组3.12,差异0.04(-0.62 to 0.69;p=0.93)。
- 血压变化:利奥西呱组-8.20 mm Hg(-10.48 to -5.91)vs 安慰剂组-1.24(-3.58 to 1.10),差异-6.96 mm Hg(90% CI -10.22 to -3.69;p<0.001)。
关键数值与推荐
- 主要结局为发生至少一次经判定的治疗出现严重不良事件的参与者比例。
- 利奥西呱起始剂量1.0 mg每日三次,最高至2.5 mg每日三次(最高耐受剂量),疗程12周。
- 若收缩压大于95 mm Hg且无低血压征象,每2周考虑增加0.5 mg;否则维持末次剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive events. METHODS: This was a phase 1-2, randomised, double blind, placebo-controlled trial. Eligible patients were 18 years or older, had confirmed sickle cell disease documented by haemoglobin electrophoresis or HPLC fractionation (haemoglobin SS, SC, Sβ-thalassemia, SD, or SO-Arab), and stage 1 hypertension or proteinuria. Participants were randomly assigned 1:1 to receive either riociguat or matching placebo via a web-based system to maintain allocation concealment. Both treatments were administered orally starting at 1·0 mg three times a day up to 2·5 mg three times a day (highest tolerated dose) for 12 weeks. Dose escalation by 0·5 mg was considered every 2 weeks if systolic blood pressure was greater than 95 mm Hg and the participant had no signs of hypotension; otherwise, the last dose was maintained. The primary outcome was the proportion of participants who had at least one adjudicated treatment-emergent serious adverse event. The analysis was performed by the intention-to-treat. This trial is registered with ClinicalTrials.gov (NCT02633397) and was completed. FINDINGS: Between April 11, 2017, and Dec 31, 2021, 165 participants were screened and consented to be enrolled into the study. Of these, 130 participants were randomly assigned to either riociguat (n=66) or placebo (n=64). The proportion of participants with at least one treatment-emergent serious adverse event was 22·7% (n=15) in the riociguat group and 31·3% (n=20) in the placebo group (difference -8·5% [90% CI -21·4 to 4·5]; p=0·19). A similar pattern emerged in other key safety outcomes, sickle cell related vaso-occlusive events (16·7 [n=11] vs 21·9% [n=14]; difference -5·2% [-17·2 to 6·5]; p=0·42), mean pain severity (3·18 vs 3·32; adjusted mean difference -0·14 [-0·70 to 0·42]; p=0·69), and pain interference (3·15 vs 3·12; 0·04 [-0·62 to 0·69]; p=0·93) at 12 weeks were similar between groups. Regarding the key clinical efficacy endpoints, participants taking riociguat had a blood pressure of -8·20 mm Hg (-10·48 to -5·91) compared with -1·24 (-3·58 to 1·10) in those taking placebo (-6·96 mm Hg (90% CI -10·22 to -3·69; p<0·001). INTERPRETATION: Riociguat was safe and had a significant haemodynamic effect on systemic blood pressure. The results of this study provide measures of effect and variability that will inform power calculations for future trials. FUNDING: Bayer Pharmaceuticals.
引用
- Gladwin MT, Gordeuk VR, Desai PC, et al. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024. PMID: 38554715. doi:10.1016/S2352-3026(24)00045-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。